The U.S. Food and Drug Administration (FDA) approved the antiretroviral drug maraviroc on August 6, 2007. Maraviroc, the first in a new class of oral HIV therapies known as CCR5 inhibitors, is approved for use in adult HIV-infected patients. CCR5 inhibitors work by binding to receptors on the surface of cells, preventing HIV from latching on and inserting itself into other uninfected cells. This effectively hinders the infected cells’ ability to replicate. The drug is manufactured by Pfizer Inc., a global pharmaceutical company headquartered in New York.
Read the entire FDA release.
Source: FDA news release dated August 6, 2007